Sensei Biotherapeutics, Inc. SNSE 深 滬
已收盤 09-05 16:00:00 美东时间
8.32
-0.494
-5.60%
華盛通- 最 高8.7927
- 今 開8.75
- 成交量 9890股
- 最 低 8.32
- 昨 收 8.8139
- 總市值 1048.65万
- 52周最高 17.40
- 市盈率 靜 --
- 換手率 0.78%
- 52周最低 5.00
- 委 比 0.00%
- 總股本 126.04万
- 歷史最高 530.00
- 量 比 1.61
- 振 幅 5.36%
- 歷史最低 5.00
- 每 手 1
- 風險率 0.27%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Sensei Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
<p>Sensei Biotherapeutics announced that John Celebi, its CEO, will participate in 1x1 investor meetings at the H.C. Wainwright Global Investment Conference on September 8, 2025. An on-demand corporate presentation will be available on the company's website starting September 5, 2025, and a webcast replay will be accessible for 90 days. The company focuses on developing next-generation cancer therapeutics using its TMAb platform, with its lead ca...
09-03 12:00
Sensei Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Sensei Biotherapeutics reported Q2 2025 financial results and provided updates on its clinical program for solnerstotug. The company highlighted the completion of enrollment in its Phase 1/2 trial with 64 patients, including those with PD-(L)1 resistant tumors. Solnerstotug demonstrated favorable safety profiles and efficacy signals, with full dose expansion data expected by year-end 2025. The company also mentioned plans for multiple Phase 2 stu...
08-05 11:30
Sensei Biotherapeutics to Present Clinical Data from the Phase 1 Dose Expansion Cohort of Solnerstotug at the ESMO Congress 2025
Sensei Biotherapeutics宣布其新型抗癌疗法solnerstotug的临床数据将在2025年10月17日至21日于柏林举行的欧洲医学肿瘤学会(ESMO)大会上以小型口头报告形式展示。该数据来自solnerstotug联合再生元PD-1抑制剂Libtayo的1/2期临床试验剂量扩展队列。报告摘要编号为3933，将在10月17日下午2:00至3:30 CEST期间由START圣安东尼奥临床研究联合主任Kyriakos Papadopoulos博士呈现。Sensei公司专注于通过其专有的TMAb平台开发下一代癌症治疗药物，solnerstotug为其主打产品。
07-30 11:30
Sensei Biotherapeutics To Implement 1-For-20 Reverse Stock Split Of Issued And Outstanding Shares, Effective June 16, 2025
Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that it will implement a
06-13 19:31
Sensei Biotherapeutics Announces 1-for-20 Reverse Stock Split
Sensei Biotherapeutics plans a 1-for-20 reverse stock split effective June 16, 2025, to meet Nasdaq's minimum bid price requirement. The split will reduce issued shares from ~25.2 million to ~1.3 million, adjust stock options and equity plans proportionally, and distribute cash for fractional shares. The stock will trade under "SNSE" with a new CUSIP from June 17. The move aims to maintain the company's listing compliance.
06-13 11:30
美股大行评级 | 再生元制药遭大摩下调评级，Aspen Insurance Hldgs(AHL)获多家机构首予“超配”评级！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1136585934532136961.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Vera Therapeutics(VERA)"买入"评级，目标价从75美元升至85美元</p> <p>• Ascendiant Capital：维持60 Degrees
06-03 09:06
HC Wainwright & Co. Assumes Sensei Biotherapeutics at Buy, Announces Price Target of $5
HC Wainwright & Co. analyst Matthew Kelsey assumes Sensei Biotherapeutics (NASDAQ:SNSE) with a Buy rating and announces Price Target of $5.
06-02 21:33
Sensei Biotherapeutics GAAP EPS of -$0.27
Sensei Biotherapeutics press release (NASDAQ:SNSE): Q1 GAAP EPS of -$0.27. Cash, cash equivalents and marketable securities were $34.3 million as of March 31, 2025, as compared to $41.3 million as of ...
05-06 23:15
美股机会日报丨“黑色星期一”来袭？美国关税公布在即；特斯拉盘前大跌6%，交付数据公布在即
“黑色星期一”来袭？美国关税公布在即，恐慌指数飙升；本月二次下调！高盛大砍标普500指数目标点位；特斯拉盘前大跌6%，交付数据公布在即>>
03-31 20:22
Sensei Biotherapeutics (SNSE) Gets a Buy from Oppenheimer
In a report released on March 28, Francois Brisebois from Oppenheimer maintaine...
03-30 21:55
